Newsroom

LOTTE BIOLOGICS announced on December 16th that it held the inauguration ceremony for its new CEO and President, James Park.

The event was held at the site of LOTTE BIOLOGICS' Songdo Bio Campus, which is currently under construction with the goal of Plant 1 being operational by 2027.

With employees participating both online and offline, the event began with a welcoming address from Michael Hausladen, head of the U.S. subsidiary, and the leadership team of the Syracuse Bio Campus. This was followed by an inaugural speech from CEO Park, outlining key themes for successfully driving future business initiatives. After the ceremony, a site tour was conducted with the leadership team, and a discussion session was held with employees.

At the inauguration ceremony, CEO Park stated, "I am thrilled to embark on this new journey with the employees of LOTTE BIOLOGICS," adding, "I will strive to create an environment where all employees can work with passion." He further highlighted three core goals for LOTTE BIOLOGICS: establishing world-class pharmaceutical manufacturing facilities, building trust-based partnerships, and achieving rapid growth through the adoption of innovative technologies.

CEO Park stated, " "Since breaking ground on the first plant last March, we must prioritize safety and proactively address potential risks to strengthen our future competitiveness as we fully enter the Songdo era." He further emphasized, "We will proactively prepare to receive early orders for Plant 1 of the Songdo Bio Campus, building a solid track record from the outset and paving the way for sustainable growth."

He also addressed employees, stating, "As one team moving toward a shared goal, our technology, quality, and trust with customers will become the driving forces behind LOTTE BIOLOGICS." He added, "LOTTE BIOLOGICS, which is creating a new history, will become a global hub for biopharmaceutical production and a source of pride for the LOTTE Group."

James Park, CEO of LOTTE BIOLOGICS, holds a Bachelor of Science in Chemical Engineering from the University of California, Davis, and a Master of Science in Industrial Engineering from Columbia University. He has built an impressive career, working at global pharmaceutical companies such as Merck and Bristol-Myers Squibb (BMS). He also served as the Head of Global Business Operations (Vice President) at Samsung Biologics and most recently held the position of CEO at GC Cell, a company specializing in Cell and Gene Therapies (CGT).